Search research articles
Contact Us
Filters
Showing results (91-100 of 173) with videos related to
Page
of 18
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 2, 2020
Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study
Dana Chase, Helen Q Huang, Bradley J Monk, et al.
Nature Communications
|
July 15, 2021
SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade
Octavio A Romero, Andrea Vilarrubi, Juan J Alburquerque-Bejar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 6, 2019
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial
R Wendel Naumann, Antoine Hollebecque, Tim Meyer, et al.
Journal of Gynecologic Oncology
|
July 20, 2024
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer
Alexander B Olawaiye, Jae-Weon Kim, Andrea Bagameri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2025
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma
Joyce F Liu, Nicoletta Colombo, Amit M Oza, et al.
Journal for Immunotherapy of Cancer
|
January 22, 2022
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study
Ana Oaknin, Lucy Gilbert, Anna V Tinker, et al.
Gynecologic Oncology
|
September 2, 2018
The genetic landscape of 87 ovarian germ cell tumors
Els Van Nieuwenhuysen, Pieter Busschaert, Patrick Neven, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 23, 2022
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
Alessandro D Santin, Ignace Vergote, Antonio González-Martín, et al.
The Lancet. Oncology
|
April 12, 2024
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial
Ana Oaknin, Kathleen Moore, Tim Meyer, et al.
Gynecologic Oncology
|
January 11, 2024
Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial
Claire F Friedman, Anishka D'Souza, Diana Bello Roufai, et al.
Page
of 18
Search research articles
Search
Showing results (91-100 of 173) with videos related to
Sort By:
Page
of 18
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 2, 2020
Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study
Dana Chase, Helen Q Huang, Bradley J Monk, et al.
Nature Communications
|
July 15, 2021
SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade
Octavio A Romero, Andrea Vilarrubi, Juan J Alburquerque-Bejar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 6, 2019
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial
R Wendel Naumann, Antoine Hollebecque, Tim Meyer, et al.
Journal of Gynecologic Oncology
|
July 20, 2024
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer
Alexander B Olawaiye, Jae-Weon Kim, Andrea Bagameri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2025
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma
Joyce F Liu, Nicoletta Colombo, Amit M Oza, et al.
Journal for Immunotherapy of Cancer
|
January 22, 2022
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study
Ana Oaknin, Lucy Gilbert, Anna V Tinker, et al.
Gynecologic Oncology
|
September 2, 2018
The genetic landscape of 87 ovarian germ cell tumors
Els Van Nieuwenhuysen, Pieter Busschaert, Patrick Neven, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 23, 2022
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
Alessandro D Santin, Ignace Vergote, Antonio González-Martín, et al.
The Lancet. Oncology
|
April 12, 2024
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial
Ana Oaknin, Kathleen Moore, Tim Meyer, et al.
Gynecologic Oncology
|
January 11, 2024
Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial
Claire F Friedman, Anishka D'Souza, Diana Bello Roufai, et al.
Page
of 18